Trials / Terminated
TerminatedNCT03228186
Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer
Phase II Trial of Pevonedistat (TAK-924) Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- University of Michigan Rogel Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a single institution Phase II single arm trial to assess the efficacy of the combination of pevonedistat plus docetaxel in patients with previously treated advanced NSCLC (non-small cell lung cancer).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pevonedistat | 25mg/m2 days 1, 3, 5 |
| DRUG | Docetaxel | 75mg/m2 day 1 |
Timeline
- Start date
- 2018-03-05
- Primary completion
- 2021-11-04
- Completion
- 2021-11-04
- First posted
- 2017-07-24
- Last updated
- 2023-10-23
- Results posted
- 2023-10-23
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03228186. Inclusion in this directory is not an endorsement.